To evaluate the clinical efficacy of Neurophet AQUA, the research team analyzed white matter hyperintensities (WMH) and gray matter volume of the participants. The results showed a strong correlation between the analyses performed by Neurophet AQUA and expert medical assessments for WMH (ρ=0.66, p<0.0001). In addition, Neurophet AQUA demonstrated a high correlation with existing automated tools (LST, CAT12), with correlation coefficients ranging from ρ=0.84 to 0.85 (p<0.0001). Donghyeon Kim, Co-CEO of Neurophet, said, "This study demonstrated the clinical validity of Neurophet AQUA in a patient cohort from Singapore. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".